HDAC3-IN-2 is a pyrazinecarbohydrazide-based HDAC3 inhibitor (IC50: 14 nM) that potently targets triple-negative breast cancer cells; it exhibits cytotoxicity against 4T1 (IC50: 0.55 μM) and MDA-MB-231 (IC50: 0.74 μM) cells; demonstrates in vivo antitumor efficacy in tumor-bearing mouse models; selectively increases acetylation levels of H3K9, H3K27, and H4K12; upregulates apoptosis-related proteins caspase-3, caspase-7, and cytochrome c; and downregulates proliferation-associated proteins Bcl-2, CD44, EGFR, and Ki-67.